Cellseed Inc. · TSE:7776
Cellseed — FY2019 Earnings Presentation
31 slides from Cellseed's earnings presentation, Mar 6, 2020
Slide 1: Fiscal 2019 Earnings Results Presentation
CellSeed Inc. Fiscal 2019 Earnings Results Presentation JASDAQ Growth Stock Code: 7776
Slide 2: Contents
Contents Company Profile Financial Summary FY12/2019 Mid-term Business Plan Fiscal Year 2020 to Fiscal Year 2022 Copyright © 2020 CellSeed Inc. All Rights Reserved. 1
Slide 3: CellSeed Inc. Corporate Information
CellSeed Inc. Corporate Information Established May, 2001 Core competence Cell Sheet Engineering based on Temperature Responsive Polymers Listed JASDAQ（7776) in 2010 Business Regenerative Medical Regenerative Medicine Products Business Supporting Business • Commercialization of Cell Sheet Therapies
Slide 4: Our Business Model
Our Business Model Medical Hospitals Seeds Products Patients Treatment University Base of Innovation Collaborative Fee Medical Research Expenses Business Alliance Partner Companies Mission We take the initiative of contributing to global health care in the valuable and innovative field of regenerati
Slide 5: Development of Treatment Using Cell Sheet Engineering
Development of Treatment Using Cell Sheet Engineering Esophagus Cartilage Cornea Periodonrium Middle ear Cell Sheet Pancreas Liver Heart Lung Copyright © 2020 CellSeed Inc. All Rights Reserved. 4
Slide 6: Expansion of Cell Sheet Engineering
Expansion of Cell Sheet Engineering 120 CSTEC 総出願件数 Patents 100 Papers ⽂献数 80 60 40 20 0 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Establishment of Overseas sales for CellSeed Inc Upcell🄬 launched…
Slide 7: Contents
Contents Company Profile Financial Summary FY12/2019 Mid-term Business Plan Fiscal Year 2020 to Fiscal Year 2022 Copyright © 2020 CellSeed Inc. All Rights Reserved. 6
Slide 8: Financial Summary for the Fiscal Year Ending December 2019
Financial Summary for the Fiscal Year Ending December 2019 (Unit: Million yen; Presented with fractions less than one million yen rounded off) Profit Profit per Net Operating Ordinary attributable share— Sales Profit Profit to owners of basic parent Forecast（Ａ） 300 -1,100 -1,100 -1,100 -93.6 Actual（
Slide 9: Epithelial Cell Sheet for Esophageal Regeneration (CLS2702C/D)
Epithelial Cell Sheet for Esophageal Regeneration (CLS2702C/D) A medical treatment developed by Tokyo Women’s Medical University as a regenerative treatment for esophageal cancer (to heal esophageal wound and prevent stricture) Cell sheet is on a temperature-responsive cell culture ware and then
Slide 10: Clinical Research and Clinical Trials of Esophageal Cell Sheet
Clinical Research and Clinical Trials of Esophageal Cell Sheet Tokyo Women’s Medical University Clinical Research at Universities 2008－2014＜Japan＞ Tokyo Womenʼs Medical Univ. 10case Tokyo Womenʼs Medical Univ. Basic 10case Development and Nagasaki Univ. Agreement ＜Europe＞ Karolinska University Hos
Slide 11: Cell Sheet Regenerative Medicine Business in the Fiscal Year Ended December 2019
Cell Sheet Regenerative Medicine Business in the Fiscal Year Ended December 2019 Epithelial Cell Sheet for Esophageal Regeneration Clinical trial for obtaining approval Summer in 2016 Clinical trial commenced. 1Q in 2019 Clinical trial finished. From 2019 Having a discussion with PMDA about addi
Slide 12: Chondrocyte Sheet
Chondrocyte Sheet Disease characteristics • Causes︓ageing・obesity traumatic・ • No treatment to regenerate lost cartilage is available In Japan, estimated number of potential patients 25,300,000 persons of which, 8,000,000 shows symptoms (22nd Century Medical and Research Center) Go Omori, Yoshio
Slide 13: Overview of Chondrocyte Sheet Project
Overview of Chondrocyte Sheet Project Taiwan Basic Development Agreement Developed by Prof. Masato Sato, Department of Orthopaedic Surgery, Surgical Science, Tokai University School of Medicine ＜ Autologous Cells ＞ • 2019/1 • Licensing out Autologous cell approved by the MHLW in the 71st sheet to Me
Slide 14: Autologous chondrocyte sheets
Autologous chondrocyte sheets Collect Autologous Manufacture Cell Transplant to Patient Cartilage Cells Sheet chondrocyte sheets Indications︓Knee Osteoarthritis Copyright © 2020 CellSeed Inc. All Rights Reserved. 13
Slide 15: Allogeneic chondrocyte sheets
Allogeneic chondrocyte sheets Preparation of Cell Stock Master Working Cell Cell Bank Bank Cell Suspension Culture Evaluation test Quality/Safety In liq.Nitrogen In liq.Nitrogen Transport- ation Polydactyly donors Collection of tissue Manufacture Packaging Lot release test Thawing Culture CellSheet
Slide 16: Cell Sheet Regenerative Medicine Business in the Fiscal Year Ended December 2019
Cell Sheet Regenerative Medicine Business in the Fiscal Year Ended December 2019 Regenerated Cartilage Sheet Autologous Chondrocyte Sheet Jan. 2019 “The cartilage regeneration treatment with autologous cell sheets” proposed by Tokai University Hospital, with which we conduct joint research, wa
Slide 17: CellSeed Temperature Sensitive Cell Cultureware Lineup
CellSeed Temperature Sensitive Cell Cultureware Lineup UpCell® RepCell TM HydroCell ™ Cell Sheet Recovery Cell Recovery Ultra-Low Adhesion Cell （Temperature Sensitive） （Temperature Sensitive） Cultureware 3 x 3 mm Grid Wall Copyright © 2020 CellSeed Inc. All Rights Reserved. 16
Slide 18: Acquisition of ISO 9001: 2015 Certification
Acquisition of ISO 9001: 2015 Certification We offer consistent quality and services in the design of and manufacturing control of cell cultureware. To further improve client satisfaction, we have constructed a quality management system and acquired certification under the international standard, IS
Slide 19: Regenerative Medicine Supporting Business
Regenerative Medicine Supporting Business 1. Regenerative Cell Sheet 2. Facility Management, Product Manufacture Method 3. Cell Culturing Technician Application Submission Development, Consigned Training Support Manufacture Consigned manufacture Support for certification Cell sheet culturing
Slide 20: Regenerative Medicine Supporting Business in the Fiscal Year Ended December 2019
Regenerative Medicine Supporting Business in the Fiscal Year Ended December 2019 Variation in sales of equipment Sales of Equipment We collected information on sales of equipment from major distributors and conducted marketing activities in cooperation with distributors for sales promotion. We
Slide 21: Close collaboration with academia
Close collaboration with academia 1st Cell Sheet Engineering Innovation Forum July 19, 2019 200 people attended Keynote speech ︓Prof. Teruo Okano Presentations of clinical applications • Dr. Takanori Iwata : periodontal ligament • Dr. Goshi Shiota : liver diseases • Dr. Shuichi Sekine : constr
Slide 22: Production of Application Notes
Production of Application Notes Dr. Tetsuya Imamura of Shinshu University At the first cell sheet engineering innovation forum, he received the most excellent poster award. He engages in regenerative medicine research with the tissue engineering method using mesenchymal stem cells in the departmen
Slide 23: 2nd Cell Sheet Engineering Innovation Forum
2nd Cell Sheet Engineering Innovation Forum Date : October 15, 2020 Venue : Miraikan Capacity : 200 people : “Cell Sheet” or research using Theme ”temperature-responsive cell cultureware” • Dr. Tatsuya Shimizu (Tokyo Women’s Medical Univ. ) Presentations of • Dr. Yuji Miyahara clinical (To
Slide 24: Other activities FY12/2019
Other activities FY12/2019 Nov. 2019: Our company and MetaTech in Taiwan took the initiative in joint investment. Dec. 2019: Held a press conference in cooperation with MetaTech at Healthcare EXPO TAIWAN. Jan. 2020: Established a joint venture. Copyright © 2020 CellSeed Inc. All Rights Reserve
Slide 25: Establishing Up Cell Biomedical Co.
Establishing Up Cell Biomedical Co. Name Up Cell Biomedical Co. 14F.-2, No. 75, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei Address City 221, Taiwan (R.O.C.) Representative President Andrew H.-J. Wang establish utilize the seeds technology provided by Japanese or Taiwanese universities and resea
Slide 26: Overview of Up Cell Biomedical Inc.
Overview of Up Cell Biomedical Inc. Board Members President / Andrew H.-J. Wang Vice President / Ho Hung-Neng Seed Products Treatment Director / Setsuko Hashimoto technologies Hospitals Universities/ Patients hospitals Advisor (Taiwan and Japan) Joint Yang, Zhi-Hui research Compensation
Slide 27: Promoting Global Business Alliances
Promoting Global Business Alliances Scheduled Participation in Exhibitionsin 2020 (Outside Japan) May / China BIO (Suzhou) December / BioUS (San Diego) June / Bio Asia Taiwan (Taipei) July / BIO Partnering APAC 2020 (Shanghai) September / BIOEU Fall (Germany) October / Healthcare EXPO
Slide 28: Contents
Contents Company Profile Financial Summary FY12/2019 Mid-term Business Plan Fiscal Year 2020 to Fiscal Year 2022 Copyright © 2020 CellSeed Inc. All Rights Reserved. 27
Slide 29: Mid-term Business Plan Fiscal Year 2020 to Fiscal Year 2022
Mid-term Business Plan Fiscal Year 2020 to Fiscal Year 2022 Epithelial Cell Sheets Chondrocyte Sheet Chondrocyte Sheet Third Line of for Esophageal (Autologous Cells) (Allogeneic Cells) Products Regeneration Proceed the contract Acceleration of building Discussions for further Discussions are moving
Slide 30: Mid-term Business Plan (2020 – 2022) Financial Targets
Mid-term Business Plan (2020 – 2022) Financial Targets (Unit: Million yen; Presented with fractions less than one million yen rounded off) Profit Net Sales Operating Profit Ordinary Profit attributable to owners of parent FY2020 （Estimate） 310 -1,020 -1,020 -1,020 FY2021 （Target） 360 -1,030 -1,030 -
Slide 31: This presentation is made by CellSeed Inc. solely for disclosure of financial statements
This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions. Copyright © 2020 CellSeed Inc. All Rights Reserved. 30